Display options
Cite
Turan N, Benekli M, Dane F, et al. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thorac Cancer. 2014;5(5):398-404doi: 10.1111/1759-7714.12107.
Turan, N., Benekli, M., Dane, F., Unal, O. U., Kara, H. V., Koca, D., Balvan, O., Eren, T., Tastekin, D., Helvaci, K., Berk, V., Demirci, U., Ozturk, S. C., Dogan, E., Cetin, B., Kucukoner, M., Tonyali, O., Tufan, G., Oztop, I., Gumus, M., Coskun, U., Uner, A., Ozet, A., Buyukberber, S. (2014). Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thoracic cancer, 5(5), 398-404. https://doi.org/10.1111/1759-7714.12107
Turan, Nedim, et al. "Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer." Thoracic cancer vol. 5,5 (2014): 398-404. doi: https://doi.org/10.1111/1759-7714.12107
Turan N, Benekli M, Dane F, Unal OU, Kara HV, Koca D, Balvan O, Eren T, Tastekin D, Helvaci K, Berk V, Demirci U, Ozturk SC, Dogan E, Cetin B, Kucukoner M, Tonyali O, Tufan G, Oztop I, Gumus M, Coskun U, Uner A, Ozet A, Buyukberber S. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thorac Cancer. 2014 Sep;5(5):398-404. doi: 10.1111/1759-7714.12107. Epub 2014 Aug 25. PMID: 26763794; PMCID: PMC4704370.
Copy Download .nbib Format: NLM
Share it on

Thorac Cancer. 2014 Sep;5(5):398-404. doi: 10.1111/1759-7714.12107. Epub 2014 Aug 25.

Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer.

Thoracic cancer

Nedim Turan, Mustafa Benekli, Faysal Dane, Olcun Umit Unal, Hasan Volkan Kara, Dogan Koca, Ozlem Balvan, Tulay Eren, Didem Tastekin, Kaan Helvaci, Veli Berk, Umut Demirci, Selcuk Cemil Ozturk, Erkan Dogan, Bulent Cetin, Mehmet Kucukoner, Onder Tonyali, Gulnihal Tufan, Ilhan Oztop, Mahmut Gumus, Ugur Coskun, Aytug Uner, Ahmet Ozet, Suleyman Buyukberber,

Affiliations

  1. Department of Medical Oncology, Malatya State Hospital Malatya, Turkey.
  2. Department of Medical Oncology, Gazi University Faculty of Medicine Ankara, Turkey.
  3. Department of Medical Oncology, Marmara University Faculty of Medicine Istanbul, Turkey.
  4. Department of Medical Oncology, Dokuz Eylül University Faculty of Medicine Izmir, Turkey.
  5. Department of Thoracic Surgery, Marmara University Faculty of Medicine Istanbul, Turkey.
  6. Department of Medical Oncology, Regional Training and Research Hospital Van, Turkey.
  7. Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital Istanbul, Turkey.
  8. Department of Medical Oncology, Numune Education and Research Hospital Ankara, Turkey.
  9. Department of Medical Oncology, Necmettin Erbakan University Faculty of Medicine Konya, Turkey.
  10. Department of Medical Oncology, Dr Abdurrahman Yurtaslan Education and Research Hospital Ankara, Turkey.
  11. Department of Medical Oncology, Erciyes University Faculty of Medicine Kayseri, Turkey.
  12. Department of Medical Oncology, Ad?yaman University Education and Research Hospital Ad?yaman, Turkey.
  13. Department of Medical Oncology, Dicle University Faculty of Medicine Diyarbakir, Turkey.
  14. Department of Medical Oncology, Antakya State Hospital Hatay, Turkey.
  15. Department of Medical Oncology, Rize Education and Research Hospital Rize, Turkey.

PMID: 26763794 PMCID: PMC4704370 DOI: 10.1111/1759-7714.12107

Abstract

INTRODUCTION: We investigated the impact of modern chemotherapy regimens and bevacizumab following pulmonary metastasectomy (PM) from metastatic colorectal cancer (CRC).

METHODS: A total of 122 consecutive patients who were curatively resected for pulmonary metastases of CRC in twelve oncology centers were retrospectively analysed between January 2000 and April 2012.

RESULTS: Of 122 patients, 14 did not receive any treatment following PM. The remaining 108 patients received fluoropyrimidine-based (n = 12), irinotecan-based (n = 56) and oxaliplatin-based (n = 40) chemotherapy combinations. Among these, 52 patients received bevacizumab (BEV) while 56 did not (NoBEV). Median recurrence-free survival (RFS) was 17 months and median overall survival (OS) has not been reached at a median follow-up of 25 months after PM. Three and five-year OS rates were 66% and 53%, respectively. RFS and OS were similar, irrespective of the chemotherapy regimen or BEV use. Positive pulmonary margin, KRAS mutation status, and previous liver metastasectomy were negative independent prognostic factors for RFS, while pathologically confirmed thoracic lymph node involvement was the only negative independent prognostic for OS in multivariate analysis.

CONCLUSIONS: No significant RFS or OS difference was observed in respect to chemotherapy regimens with or without BEV in patients with pulmonary metastases of CRC following curative resection.

Keywords: Adjuvant chemotherapy; bevacizumab; colorectal cancer; pulmonary metastasectomy

References

  1. J Clin Oncol. 2011 Jul 1;29(19):2675-82 - PubMed
  2. Ann Oncol. 2012 Oct;23(10):2649-55 - PubMed
  3. J Clin Oncol. 2006 Jul 20;24(21):3347-53 - PubMed
  4. J Thorac Cardiovasc Surg. 1997 Jan;113(1):37-49 - PubMed
  5. J Thorac Cardiovasc Surg. 2002 Nov;124(5):1007-13 - PubMed
  6. Lancet Oncol. 2012 Dec;13(12):1225-33 - PubMed
  7. Dis Colon Rectum. 2012 Apr;55(4):459-64 - PubMed
  8. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  9. Oncology. 2013;84(1):14-21 - PubMed
  10. Arch Bronconeumol. 2007 Jun;43(6):309-16 - PubMed
  11. Can J Surg. 2001 Jun;44(3):217-21 - PubMed
  12. J Clin Oncol. 2005 Dec 1;23(34):8671-8 - PubMed
  13. Interact Cardiovasc Thorac Surg. 2013 Aug;17(2):303-7 - PubMed
  14. N Engl J Med. 2005 Jun 30;352(26):2696-704 - PubMed
  15. N Engl J Med. 2008 Oct 23;359(17):1757-65 - PubMed
  16. J Clin Oncol. 2004 Jan 15;22(2):229-37 - PubMed
  17. J Clin Oncol. 2007 Jun 1;25(16):2198-204 - PubMed
  18. Med Oncol. 2007;24(4):431-5 - PubMed
  19. Surg Oncol. 2012 Sep;21(3):237-44 - PubMed
  20. Surg Oncol. 2001 Jul-Aug;10(1-2):35-42 - PubMed
  21. BMC Cancer. 2012 Aug 01;12:326 - PubMed
  22. Br J Cancer. 2001 Sep 1;85(5):692-6 - PubMed
  23. N Engl J Med. 2000 Sep 28;343 (13):905-14 - PubMed
  24. Thorax. 2012 Feb;67(2):185-7 - PubMed
  25. J Natl Cancer Inst. 2005 Jul 6;97(13):981-9 - PubMed
  26. Br J Surg. 2004 Jan;91(1):112-20 - PubMed
  27. Interact Cardiovasc Thorac Surg. 2009 Oct;9(4):640-4 - PubMed
  28. J Thorac Oncol. 2010 Jun;5(6 Suppl 2):S172-8 - PubMed
  29. PLoS One. 2012;7(10):e47345 - PubMed
  30. Ann Thorac Surg. 2007 Jul;84(1):324-38 - PubMed
  31. Int J Colorectal Dis. 2007 Jun;22(6):699-704 - PubMed
  32. Oncologist. 2009 Jan;14 (1):22-8 - PubMed
  33. J Clin Oncol. 2007 Oct 20;25(30):4779-86 - PubMed
  34. World J Gastroenterol. 2012 Feb 21;18(7):662-5 - PubMed
  35. Ann Surg Oncol. 2013 Feb;20(2):572-9 - PubMed
  36. Semin Oncol. 1999 Oct;26(5):485-98 - PubMed
  37. J Clin Oncol. 2011 Jan 1;29(1):11-6 - PubMed

Publication Types